全文获取类型
收费全文 | 53364篇 |
免费 | 4348篇 |
国内免费 | 1028篇 |
专业分类
耳鼻咽喉 | 276篇 |
儿科学 | 732篇 |
妇产科学 | 1205篇 |
基础医学 | 3403篇 |
口腔科学 | 861篇 |
临床医学 | 10277篇 |
内科学 | 4691篇 |
皮肤病学 | 393篇 |
神经病学 | 1610篇 |
特种医学 | 906篇 |
外国民族医学 | 13篇 |
外科学 | 4841篇 |
综合类 | 8524篇 |
现状与发展 | 7篇 |
一般理论 | 3篇 |
预防医学 | 11558篇 |
眼科学 | 340篇 |
药学 | 4962篇 |
133篇 | |
中国医学 | 1239篇 |
肿瘤学 | 2766篇 |
出版年
2024年 | 80篇 |
2023年 | 947篇 |
2022年 | 1529篇 |
2021年 | 2588篇 |
2020年 | 2944篇 |
2019年 | 1845篇 |
2018年 | 1791篇 |
2017年 | 1898篇 |
2016年 | 1993篇 |
2015年 | 2089篇 |
2014年 | 4487篇 |
2013年 | 4241篇 |
2012年 | 3847篇 |
2011年 | 3908篇 |
2010年 | 3250篇 |
2009年 | 2796篇 |
2008年 | 2857篇 |
2007年 | 2608篇 |
2006年 | 2329篇 |
2005年 | 1865篇 |
2004年 | 1624篇 |
2003年 | 1305篇 |
2002年 | 960篇 |
2001年 | 769篇 |
2000年 | 632篇 |
1999年 | 519篇 |
1998年 | 457篇 |
1997年 | 352篇 |
1996年 | 313篇 |
1995年 | 251篇 |
1994年 | 217篇 |
1993年 | 167篇 |
1992年 | 121篇 |
1991年 | 145篇 |
1990年 | 119篇 |
1989年 | 95篇 |
1988年 | 77篇 |
1987年 | 66篇 |
1986年 | 64篇 |
1985年 | 91篇 |
1984年 | 95篇 |
1983年 | 59篇 |
1982年 | 71篇 |
1981年 | 58篇 |
1980年 | 64篇 |
1979年 | 29篇 |
1978年 | 36篇 |
1977年 | 24篇 |
1976年 | 25篇 |
1975年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
5.
Lei Yang You-Ling Shi Yan Ma Wei-Wei Ren Guang-Ming Pang Jiao Liu 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2022,130(1):43-52
Krüppel-like factor 16 (KLF16), a member of the Krüppel-like factor (KLF) family, has been extensively investigated in multiple cancer types. However, the role of KLF16 in oral squamous cell carcinoma (OSCC) remains unknown. Thus, we conducted this study to investigate its related mechanism. KLF16 expression in OSCC cell lines was quantified by western blotting. Then, OECM1 and OC3 cells were divided into Blank, siCtrl, siKLF16#1 and siKLF16#2 groups. Subsequently, cell proliferation was detected using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assays, cell migration and invasion were detected with wound healing and Transwell assays, and cell cycle distribution and cell apoptosis were detected via flow cytometry. KLF16, p21, CDK4, Cyclin D1 and p-Rb expression was detected by western blotting. Finally, xenograft models were established in nude mice to observe the in vivo effects of KLF16 on OSCC. KLF16 protein expression was upregulated in OSCC cells. Compared to the cells in the Blank group, the OECM1 and OC3 cells in the siKLF16#1 group and siKLF16#2 group exhibited a sharp decrease in proliferation but a remarkable increase in apoptosis. Moreover, the proportion of cells in the G0/G1 phase notably increased and that in the S phase decreased, with evident decreases in cell invasion and migration. Moreover, KLF16, cyclin-dependent kinase 4 (CDK4), Cyclin D1 and p-Rb protein expression was upregulated, but p21 expression was downregulated. The mice in the siKLF16#1 and siKLF16#2 xenograft model groups exhibited slower tumour growth and smaller tumours with evident downregulation of Ki67 expression compared to the mice in the Blank group. KLF16 expression was upregulated in OSCC cells, and interfering with KLF16 led to cell cycle arrest, inhibited OSCC cell growth and promoted cell apoptosis. 相似文献
6.
《Journal of Radiology Nursing》2022,41(2):123-128
ObjectiveThe objective of this study was to reduce errors in a pathologic specimen with the help of a protocol systematizing the pathology specimen management process in the operating room.Materials and methodThis quasi-experimental study was carried out in the operating room unit of a research and training hospital. A protocol systematizing the process of specimen management in secure surgical pathology and prepared in light of the current literature was used as an intervention, and the effectiveness of the protocol was tested.ResultsIt was determined that the rate of adverse events decreased from .3226% (68 of 21,078) to .032% (6 of 18,706) after the protocol systematizing the surgical pathology specimen management process prepared by the researchers, and the protocol was found to be effective by 90% (P = .03).ConclusionBased on the data obtained in this study, we recommend the use of a pathologic specimen management protocol in the operating room. 相似文献
7.
8.
Platelets are needed to prevent or arrest bleeding and aggregate at the site of injury upon vascular damage. Platelets express receptors for estrogens which might affect the function of the platelets and their hemostatic ability. The aim was to identify possible differences in platelet function related to age, gender, and phases of the menstrual cycle by use of impedance aggregometry with Multiplate. In the first part of the study, platelet function was assessed in 60 healthy individuals (30 men and 30 women) in each of three age groups (20–25, 40–45, and 60–65 years). In the second part of the study, the platelet function was analyzed on four occasions during the menstrual cycle in women without oral contraceptives (OCs) (n = 17) and compared to 19 women on OCs and 18 men of similar age (20–40 years). For the women on OCs, aggregation was analyzed once during the tablet-free week and once late during the period with OCs. The men were sampled once. Women of younger age (<45 years) had significantly higher agonist-induced aggregation response than both men and post-menopausal women (60–65 years). The agonist-induced aggregation response did not differ between phases of the menstrual cycle or OC use. The results suggest that estradiol and/or progesterone affect spontaneous aggregation since it was found to be lowest in the mid-luteal phase. Spontaneous aggregation was significantly lower in women on OCs than in both men and women without OCs. Our findings indicate that fertile age is associated with higher aggregation response capacity of the platelets, possibly to prevent excessive bleeding during menstruation, but this response capacity is not altered during the menstrual cycle or by use of OCs. 相似文献
9.
Michael Staehler Peter J. Goebell Lothar Müller Till-Oliver Emde Natalie Wetzel Lisa Kruggel Martina Jänicke Norbert Marschner the RCC-Registry Group 《International journal of cancer. Journal international du cancer》2020,146(5):1307-1315
Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC. 相似文献
10.